Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaMeasurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled CompoundsThe effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycinSuccessful management of discovered pH dependence in vancomycin recovery studies: novel HPLC method for microdialysis and plasma samples.Epidemiology of community-onset Staphylococcus aureus infections in pediatric patients: an experience at a Children's Hospital in central Illinois.Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia.Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infectionsContinuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized studyClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogramLinezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Penetration of vancomycin into epithelial lining fluid in healthy volunteers.Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics.Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia.Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.Predictors of mortality in Staphylococcus aureus BacteremiaPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trialFactors impacting unbound vancomycin concentrations in different patient populations.Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.The pharmacokinetic and pharmacodynamic properties of vancomycin.Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.Optimizing antibiotic treatment for ventilator-associated pneumonia.Oritavancin--an investigational glycopeptide antibiotic.Gram-positive cocci infections in intensive care: guide to antibacterial selection.Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes.Fatal persistent methicillin-resistant Staphylococcus aureus bacteremia and vascular graft infections complicated with the formation of multiple abscesses despite aggressive medical therapy.Pharmacokinetics and pharmacodynamics of antibacterial agents.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling.Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.Pneumonia caused by methicillin-resistant Staphylococcus aureus.
P2860
Q22241905-F7168034-263C-4819-A5E6-A5F126F296F4Q26738341-57E14F18-0258-49CA-920E-36DF1197C3F9Q31127012-3CA1A4A5-D069-45BC-847F-D18D01F1D434Q31131320-8576C494-42EB-4A6E-8EB8-EB35D438C714Q33483064-C2EEA6FE-4787-4909-B8F3-E90CA2E59A1FQ33612643-66C67DC0-DE8A-4499-96B1-329683F92AC5Q33881584-D17D56BB-A9D9-4B0F-AA5E-73E236904CE1Q33982863-63D136C9-69CD-4050-8F2B-02252D554420Q34157657-26B78E14-6519-4878-A04E-DC4531F8B853Q34216623-96AFDA77-B27F-4427-98B4-CE704A0C518EQ34777837-1B81DBC4-7BD9-4A6F-A40F-2DEC81B2B3BFQ34923394-B256CCBE-2E5D-4C47-A99F-CDCE7FCE99F1Q35099758-A1AE9D7A-6B24-43B4-AFF6-6A342A939284Q35123536-011A27C7-CF03-483B-90BE-05D6C2C98735Q35542062-E146F6FF-3897-4595-BD38-1832334EDCA4Q35598408-A81BA694-F6B9-4D95-9414-9B0D48034D0BQ35627857-2BCC2F22-0058-42F7-B296-4E9D26524FAFQ35780121-73C810A3-1BF2-462E-AAAB-C87D9B240E5AQ35905561-5AA01614-3743-4FC6-973D-5F15471EB83CQ35905703-C38A8C73-8352-493D-84DC-EEC779091B83Q35940556-7EDC112E-E0D7-474F-AB24-3C89A08D281BQ36083619-9E9D2F2B-F5F2-4670-AD95-8F5F0F70D725Q36093598-F011F921-4757-4907-BE7D-9D24BDC9964FQ36158421-5F43B389-17D5-41F8-ABB6-E072CE4485EDQ36295483-1379C791-8FB6-4DB5-BF8A-AD2EDD56297DQ36328971-995EF77F-C78A-4AFA-8A33-B369EBF28AC7Q36338182-096F8CA6-773D-457F-B544-7D8F0D6EF6BAQ36390901-287088B9-F046-41CF-98CA-77F276349311Q36426011-8F61AA5C-61D1-414F-9DD1-8E99B6A1790AQ36480958-CA9E6FED-C1A2-4B06-9833-344E5EEDF4EBQ36548708-8CAD8141-A32B-40B2-B97B-AD4A7DF48EAEQ36666985-7AA8ABC7-BC90-4B2C-AF5B-0BCE05AC48A8Q36777850-F60CE3FA-FCAD-4682-815D-BE7F1D938060Q36861645-63A3BCE4-15D0-4C76-981F-B73A87338118Q36871505-0A6D2EE7-6933-42E5-91A5-18CFE5358285Q36911111-3C378ABD-F802-48EA-9E38-4BF5DE282371Q36936597-35C35B5A-BECD-419B-8E1C-CF58DCC71535Q37023428-91EFE596-00EE-4248-B3ED-9C21D54658E8Q37029217-80AE4058-350D-407C-80C4-A8B979F35B1FQ37156705-EEB8700A-808D-43A6-B043-433833387E44
P2860
Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Analysis of vancomycin entry i ...... ge in critically ill patients.
@ast
Analysis of vancomycin entry i ...... ge in critically ill patients.
@en
type
label
Analysis of vancomycin entry i ...... ge in critically ill patients.
@ast
Analysis of vancomycin entry i ...... ge in critically ill patients.
@en
prefLabel
Analysis of vancomycin entry i ...... ge in critically ill patients.
@ast
Analysis of vancomycin entry i ...... ge in critically ill patients.
@en
P2093
P2860
P356
P1476
Analysis of vancomycin entry i ...... ge in critically ill patients.
@en
P2093
Dombret MC
Farinotti R
P2860
P304
P356
10.1128/AAC.37.2.281
P407
P577
1993-02-01T00:00:00Z